PharmaCyte Biotech, Inc.

PMCB

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001157075


None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $46.8M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution, late filer, thin data, degenera... not computable: distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Jul 29, 2026 95 days before the rescan; latest periodic filing 10-Q received Sep 14, 2026
Last close	$0.31 2026-10-30; market equity $3.3M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Jul 29, 2026

cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box®." The Cell-in-a-Box® technology is intended to be used as a platform upon which therapies for several types of cancer, including LAPC, will be developed. The current generation of our product candidate is referred to as "CypCaps?." Scientific Committee (the "Scientific Committee"), chaired by Dr. Michael Abecassis. The Scientific Committee and our independent consultants are reviewing many of the risks relative to our business. In addition, the Board is reviewing risks associated with our development programs and our relationship with SG Austria Pte. Ltd.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 14.7						
Gross profitability	not computable	32.4%				

latest aligned inputs end 2016-04-30; latest annual assets end 2026-04-30

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(28.0%)	(6.6%)		14.7	803	2026-04-30
Gross margin stability, five years	not computable	2.8 pts				
annual revenue must exceed $100,000						
Solvency, sleeve percentile 18.9						
Twelve-month failure probability	not computable	0.08%				
four consecutive discrete net-income quarters are required; found 4						
Altman Z double-prime	(0.16)	(0.35)		37.3	748	2026-04-30
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
interest expense must exceed $100,000						
Current ratio	45.28x	2.92x		0.4	829	2026-04-30
Growth and financing, sleeve percentile 76.5						
Revenue growth, three-year compound	not computable	10.1%				
current value must be positive and the base must exceed $100,000						
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 0						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	(13.9%)	2.2%		74.8	696	2026-04-30
Net share issuance, one year	58.0%	2.5%		78.1	631	2026-07-24

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 58.0%
Late filer	found 2 NT 10-K/Q filings in the last eight quarters
Thin data	5 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(55.8%)	(2.2%)	13
Distance from 52-week high	(75.2%)	(28.7%)	11
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	8.48	0.28	99
Sales to price	0.00	0.30	0
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.99)	(0.19)	13

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-04-30	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$17.7M
Operating cash flow, four quarters	-$3.9M
Months of runway	54.0
Days since last periodic filing	48 (10-Q received Sep 14, 2026)
Median daily dollar volume, 63 sessions	$37,529

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$0	2016-04-30	2016-07-29	10-K	16-007057
2	assets	us-gaap:Assets	$7.2M	2016-04-30	2017-07-27	10-K	17-001881
3	net income	us-gaap:NetIncomeLoss	-$19.4M	2026-04-30	2026-07-29	10-K	26-005836
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$5.2M	2026-04-30	2026-07-29	10-K	26-005836
5	assets	us-gaap:Assets	$46.8M	2026-04-30	2026-07-29	10-K	26-005836
6	assets	us-gaap:Assets	$55.2M	2025-04-30	2026-07-29	10-K	26-005836
7	revenue	us-gaap:Revenues	$0	2016-04-30	2017-07-27	10-K	17-001881
8	current assets	us-gaap:AssetsCurrent	$37.4M	2026-04-30	2026-07-29	10-K	26-005836
9	current liabilities	us-gaap:LiabilitiesCurrent	$826,424	2026-04-30	2026-07-29	10-K	26-005836
10	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$104.4M	2026-04-30	2026-07-29	10-K	26-005836
11	operating income	us-gaap:OperatingIncomeLoss	-$6.9M	2026-04-30	2026-07-29	10-K	26-005836
12	book equity	us-gaap:StockholdersEquity	$33.3M	2026-04-30	2026-07-29	10-K	26-005836
13	liabilities	us-gaap:Liabilities	$11.8M	2026-04-30	2026-07-29	10-K	26-005836
14	operating income	us-gaap:OperatingIncomeLoss	-$6.5M	2023-04-30	2024-08-13	10-K	24-005575
15	interest expense	us-gaap:InterestExpense	$0	2023-04-30	2023-07-31	10-K	23-005175
16	revenue	us-gaap:Revenues	$0	2026-04-30	2026-07-29	10-K	26-005836
17	revenue	us-gaap:Revenues	$0	2025-04-30	2026-07-29	10-K	26-005836
18	revenue	us-gaap:Revenues	$0	2024-04-30	2025-08-11	10-K	25-005821
19	revenue	us-gaap:Revenues	$0	2023-04-30	2024-08-13	10-K	24-005575
20	assets	us-gaap:Assets	$59.9M	2024-04-30	2025-08-11	10-K	25-005821
21	assets	us-gaap:Assets	$73.3M	2023-04-30	2024-08-13	10-K	24-005575
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,735,649	2026-07-24	2026-07-29	10-K	26-005836
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	6,795,779	2025-08-04	2025-08-11	10-K	25-005821

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.